Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 337

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 8
Chunk 337
---
4 was $0.1 million and $0.2 million, respectively. Depreciation expense was $0.3 million for the six months ended June 30, 2025 and 2024.

F-10

6. Accrued Expenses 

Accrued expenses consisted of the following (in thousands): June 30,2025December 31,2024Accrued research and development$2,660 $3,961 Accrued compensation and benefits1,991 2,972 Accrued professional fees782 737 Accrued other35 — Accrued offering costs— 492 Total accrued expenses$5,468 $8,162 

7. Commitments and Contingencies 

Operating Leases The Company leases office space under a noncancelable operating lease. There have been no material changes to the Company’s lease during the six months ended June 30, 2025. For additional information, see Note 7, “Leases,” in the audited consolidated annual financial statements in the Annual Report.Legal Proceedings The Company was not subject to any material legal proceedings as of June 30, 2025, and the Company is not aware of any material legal proceedings that are currently pending or threatened. Other Contracts The Company is party to various contracts with contract research organizations and contract manufacturing organizations that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There were no contractual obligations arising from these arrangements as of June 30, 2025, and December 31, 2024. Indemnification Agreements In the ordinary course of business the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date however, the Company has not incurred any material costs as a result of such indemnifications nor experienced any losses related to them. As of June 30, 2025, the Company was